BKYINasdaqServices-Prepackaged SoftwareFiscal year ends December 31
BIO KEY INTERNATIONAL INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$2.27−0.36 (-13.69%)
Close on Oct 19, 2026
- Market cap
- $2.35M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
76.9%+4.9 pts over 5 years
Operating margin
-115.0%+68.4 pts over 5 years
Net margin
-120.6%+220.5 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -14.3% | -5.4% | +15.9% | +1.2% | |
| Gross profit | -19.1% | -0.1% | +17.5% | +1.4% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -24.9% | -107.2% | -161.2% | |
| Return on assets | -22.2% | -77.3% | -84.6% | |
| Current ratio | 2.67 | 10.10 | 1.47 | |
| Debt to equity | – | – | – | |
| Net debt to EBITDA | – | – | – | |
| Interest coverage | – | -1.2× | -112.3× | |
| Inventory turnover | 2.3× | 2.1× | 3.7× | |
| Capex to revenue | 1.8% | 1.3% | 0.2% | |
| Diluted shares | 0M | 0M | 1M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Bio Key International generated $26.58M from operations and spent $150.12K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$26.58M
Used
$150.12K
Capital expenditure$150.12K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-120.6%
×Asset turnover0.70×
×Equity multiplier1.91×
=Return on equity, FY2025-161.2%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -120.6% | 0.70× | 1.91× | -161.2% |
| FY2024 | -62.1% | 1.06× | 2.72× | -177.9% |
| FY2023 | -109.9% | 0.98× | 2.49× | -267.8% |
| FY2022 | -169.7% | 0.48× | 1.39× | -113.9% |
| FY2021 | -99.0% | 0.25× | 1.12× | -28.2% |
| FY2020 | -341.0% | 0.23× | 1.39× | -107.2% |
| FY2019 | -643.4% | 0.32× | 1.73× | -356.6% |
| FY2018 | -169.8% | 0.29× | 1.15× | -56.7% |
| FY2017 | -67.8% | 0.38× | 1.14× | -29.3% |
| FY2016 | -140.8% | 0.16× | 1.12× | -24.9% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$7.16M
- Cash generatingOperating cash flow above zero-$4.67M
- Return on assets improvedROA up on the prior year-95.2% → -83.1%
- Earnings backed by cashOperating cash flow above net income-$4.67M vs -$7.16M
- Less leverageLong-term debt to assets fell0.0% → –
- Better liquidityCurrent ratio rose0.41 → 1.47
- No dilutionShare count did not rise0M → 1M
- Gross margin improvedGross margin up on the prior year81.39% → 76.88%
- More efficientAsset turnover rose1.53 → 0.69